HC Wainwright & Co. Reiterates Neutral on Paratek Pharmaceuticals, Maintains $2.15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Neutral rating on Paratek Pharmaceuticals (NASDAQ:PRTK) and maintained a price target of $2.15.
July 10, 2023 | 3:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Paratek Pharmaceuticals' stock rating has been reiterated as Neutral by HC Wainwright & Co. with a maintained price target of $2.15.
The reiteration of the Neutral rating and maintained price target by HC Wainwright & Co. indicates that the analyst sees no significant changes in the company's outlook. This could mean that the stock price is expected to remain stable in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100